Replies to post #12876 on Momenta Pharmaceuticals, Inc. (MNTA)

[semi_infinite]

That's a benign interpretation of TEVA's strategy. I think the safer guess is that they want to obstruct generic GA to any degree possible using whatever latest separation technology available even if the detected differences don't matter in the clinic. I note from other threads that you have lost interest in MNTA as a shareholder and that says a lot about the effectiveness of what TEVA has done.